A Cell-Type Approach to Defining Selective Vulnerability to Alzheimer’s in the Human Brain

About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2017 - June 30, 2021
Grant ID
A2017346S
Acknowledgement
Goals
A close look at brain tissue from Alzheimer’s disease (AD) patients reveals that only some types of neurons have tau neurofibrillary tangles or other signs of neurodegeneration. In contrast, others in close vicinity appear healthy. What makes some neurons more vulnerable or resistant to disease? We are using a new technique, called single-cell RNA sequencing, to isolate thousands of single neurons from human brain tissue, study all the genes that are expressed in each individual cell, and make cell-to-cell comparisons between normal, early-stage, and late-stage AD. Our studies will clarify the precise identity of neurons involved by pathology and undergoing cell death in AD, and point to the main molecular pathways that confer vulnerability or resistance to disease.
Grantee institution at the time of this grant: University of California, Los Angeles
Summary
A microscopic view of brain tissue from Alzheimer’s disease (AD) patients reveals that only some neurons display tau neurofibrillary tangles and other signs of neurodegeneration, while others in close vicinity appear healthy. What makes some neurons more vulnerable or resilient to disease?
Our studies aim to define the precise identity of neurons that are affected in AD and uncover the relevant genes and molecular pathways that confer cell-type-specific vulnerability or resilience to disease. For that, we are using quantitative neuroanatomical studies combined with single-cell RNA sequencing from postmortem human brains. Single-cell RNA sequencing is a revolutionary new approach that can isolate thousands of single cells, study gene expression in each individual cell, and make robust cell-to-cell comparisons. We are studying cortical areas that are affected at the early and late stages of disease progression to provide a comprehensive landscape of the progression of molecular changes. Neuroanatomical studies in the postmortem AD brain strengthen this study by adding validation, spatial resolution, and correlation with human pathology. The latter is key to bridge basic knowledge and clinical relevance. This study will identify the earliest affected disease pathways, as well as neuroprotective pathways, and potentially will aid early detection of AD and the design of targeted therapies.
Grants
Related Grants
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD